{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:42:49Z","timestamp":1792716169949,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s11307-025-02022-3","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T12:54:36Z","timestamp":1750942476000},"page":"506-517","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["MIB guides: [89Zr]Zr-DFO-trastuzumab and [64Cu]Cu-NOTA-Trastuzumab for Preclinical Cancer Imaging"],"prefix":"10.1007","volume":"27","author":[{"given":"Cristina","family":"Sim\u00f3","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander C.","family":"Vanover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Carmen","family":"Azevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4772-9339","authenticated-orcid":false,"given":"Patr\u00edcia M. R.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,26]]},"reference":[{"issue":"6","key":"2022_CR1","doi-asserted-by":"publisher","first-page":"e260","DOI":"10.1016\/S1470-2045(24)00041-X","volume":"25","author":"F Giammarile","year":"2024","unstructured":"Giammarile F, Paez D, Zimmermann R, Cutler CS, Jalilian A, Korde A, Knoll P, Ayati N, Lewis JS, Lapi SE, Delgado Bolton RC, Kunikowska J, Estrada Lobato E, Urbain JL, Holmberg O, Abdel-Wahab M, Scott AM (2024) Production and regulatory issues for theranostics. Lancet Oncol 25(6):e260\u2013e269. https:\/\/doi.org\/10.1016\/S1470-2045(24)00041-X","journal-title":"Lancet Oncol"},{"issue":"3","key":"2022_CR2","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1016\/S1470-2045(19)30821-6","volume":"21","author":"K Herrmann","year":"2020","unstructured":"Herrmann K, Schwaiger M, Lewis JS, Solomon SB, McNeil BJ, Baumann M, Gambhir SS, Hricak H, Weissleder R (2020) Radiotheranostics: a roadmap for future development. Lancet Oncol 21(3):e146\u2013e156. https:\/\/doi.org\/10.1016\/S1470-2045(19)30821-6","journal-title":"Lancet Oncol"},{"issue":"6","key":"2022_CR3","doi-asserted-by":"publisher","first-page":"e236","DOI":"10.1016\/S1470-2045(24)00030-5","volume":"25","author":"SE Lapi","year":"2024","unstructured":"Lapi SE, Scott PJH, Scott AM, Windhorst AD, Zeglis BM, Abdel-Wahab M, Baum RP, Buatti JM, Giammarile F, Kiess AP, Jalilian A, Knoll P, Korde A, Kunikowska J, Lee ST, Paez D, Urbain JL, Zhang J, Lewis JS (2024) Recent advances and impending challenges for the radiopharmaceutical sciences in oncology. Lancet Oncol 25(6):e236\u2013e249. https:\/\/doi.org\/10.1016\/S1470-2045(24)00030-5","journal-title":"Lancet Oncol"},{"issue":"7","key":"2022_CR4","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41568-023-00576-4","volume":"23","author":"J Schwenck","year":"2023","unstructured":"Schwenck J, Sonanini D, Cotton JM, Rammensee HG, la Fougere C, Zender L, Pichler BJ (2023) Advances in PET imaging of cancer. Nat Rev Cancer. 23(7):474\u201390. https:\/\/doi.org\/10.1038\/s41568-023-00576-4","journal-title":"Nat Rev Cancer."},{"issue":"6","key":"2022_CR5","doi-asserted-by":"publisher","first-page":"e250","DOI":"10.1016\/S1470-2045(24)00037-8","volume":"25","author":"AM Scott","year":"2024","unstructured":"Scott AM, Zeglis BM, Lapi SE, Scott PJH, Windhorst AD, Abdel-Wahab M, Giammarile F, Piaez D, Jalilian A, Knoll P, Korde A, Vichare S, Ayati N, Lee ST, Lyashchenko SK, Zhang J, Urbain JL, Lewis JS (2024) Trends in nuclear medicine and the radiopharmaceutical sciences in oncology: workforce challenges and training in the age of theranostics. Lancet Oncol 25(6):e250\u2013e259. https:\/\/doi.org\/10.1016\/S1470-2045(24)00037-8","journal-title":"Lancet Oncol"},{"issue":"12","key":"2022_CR6","doi-asserted-by":"publisher","first-page":"6311","DOI":"10.1021\/acs.molpharmaceut.4c007773","volume":"21","author":"C Sim\u00f3","year":"2024","unstructured":"Sim\u00f3 C, Shmuel S, Vanover A, Pereira PMR (2024) [64Cu]Cu-NOTA-trastuzumab and [89Zr]Zr-DFO-trastuzumab in xenografts with varied HER2 expression. Mol Pharm 21(12):6311\u201322. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.4c007773","journal-title":"Mol Pharm"},{"issue":"10","key":"2022_CR7","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.2967\/jnumed.122.265172","volume":"64","author":"EL Brown","year":"2023","unstructured":"Brown EL, Shmuel S, Mandleywala K, Panikar SS, Berry NK, Rao Y, Zidel A, Lewis JS, Pereira PMR (2023) Immuno-PET detects antibody-drug potency on coadministration with statins. J Nucl Med 64(10):1638\u201346. https:\/\/doi.org\/10.2967\/jnumed.122.265172","journal-title":"J Nucl Med"},{"issue":"11","key":"2022_CR8","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.2967\/jnumed.112.118612","volume":"54","author":"K Tamura","year":"2013","unstructured":"Tamura K, Kurihara H, Yonemori K, Tsuda H, Suzuki J, Kono Y, Honda N, Kodaira M, Yamamoto H, Yunokawa M, Shimizu C, Hasegawa K, Kanayama Y, Nozaki S, Kinoshita T, Wada Y, Tazawa S, Takahashi K, Watanabe Y, Fujiwara Y (2013) 64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer. J Nucl Med 54(11):1869\u201375. https:\/\/doi.org\/10.2967\/jnumed.112.118612","journal-title":"J Nucl Med"},{"key":"2022_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13550-015-0082-6","volume":"5","author":"H Kurihara","year":"2015","unstructured":"Kurihara H, Hamada A, Yoshida M, Shimma S, Hashimoto J, Yonemori K, Tani H, Miyakita Y, Kanayama Y, Wada Y, Kodaira M, Yunokawa M, Yamamoto H, Shimizu C, Takahashi K, Watanabe Y, Fujiwara Y, Tamura K (2015) 64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients. Eur J Nucl Med Mol Imaging Res 5:8. https:\/\/doi.org\/10.1186\/s13550-015-0082-6","journal-title":"Eur J Nucl Med Mol Imaging Res"},{"issue":"8","key":"2022_CR10","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.2967\/jnumed.122.265248","volume":"64","author":"SS Panikar","year":"2023","unstructured":"Panikar SS, Keltee N, Berry NK, Shmuel S, Fisher ZT, Brown E, Zidel A, Mabry A, Pereira PMR (2023) Metformin-induced receptor turnover alters antibody accumulation in HER-expressing tumors. J Nucl Med 64(8):1195\u2013202. https:\/\/doi.org\/10.2967\/jnumed.122.265248","journal-title":"J Nucl Med"},{"issue":"9","key":"2022_CR11","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1021\/acs.bioconjchem.7b00325","volume":"28","author":"S Heskamp","year":"2017","unstructured":"Heskamp S, Raave R, Boerman O, Rijpkema M, Goncalves V, Denat F (2017) 89Zr-immuno-positron emission tomography in oncology: state-of-the-art 89Zr radiochemistry. Bioconjugate Chem 28(9):2211\u201323. https:\/\/doi.org\/10.1021\/acs.bioconjchem.7b00325","journal-title":"Bioconjugate Chem"},{"issue":"9","key":"2022_CR12","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/jlcr.3612","volume":"61","author":"LM Carter","year":"2018","unstructured":"Carter LM, Poty S, Sharma SK, Lewis JS (2018) Preclinical optimization of antibody-based radiopharmaceuticals for cancer imaging and radionuclide therapy-Model, vector, and radionuclide selection. J Labelled Comp Radiopharm 61(9):611\u201335. https:\/\/doi.org\/10.1002\/jlcr.3612","journal-title":"J Labelled Comp Radiopharm"},{"issue":"1","key":"2022_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.nucmedbio.2012.08.004","volume":"40","author":"MA Deri","year":"2013","unstructured":"Deri MA, Zeglis BM, Francesconi LC, Lewis JS (2013) PET imaging with 89Zr: from radiochemistry to the clinic. Nucl Med Biol 40(1):3\u201314. https:\/\/doi.org\/10.1016\/j.nucmedbio.2012.08.004","journal-title":"Nucl Med Biol"},{"issue":"1","key":"2022_CR14","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1038\/s41467-022-30142-9","volume":"13","author":"PMR Pereira","year":"2022","unstructured":"Pereira PMR, Mandleywala K, Monette S, Lumish M, Tully KM, Panikar SS, Cornejo M, Mauguen A, Ragupathi A, Keltee NC, Mattar M, Janjigian YY, Lewis JS (2022) Caveolin-1 temporal modulation enhances antibody drug efficacy in heterogeneous gastric cancer. Nat Commun 13(1):2526. https:\/\/doi.org\/10.1038\/s41467-022-30142-9","journal-title":"Nat Commun"},{"issue":"3","key":"2022_CR15","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2967\/jnumed.119.230961","volume":"61","author":"E Berg","year":"2020","unstructured":"Berg E, Gill H, Marik J, Ogasawara A, Williams S, van Dongen G, Vugts D, Cherry SR, Tarantal AF (2020) Total-body PET and highly stable chelators together enable meaningful 89Zr-antibody PET studies up to 30 days after injection. J Nucl Med 61(3):453\u201360. https:\/\/doi.org\/10.2967\/jnumed.119.230961","journal-title":"J Nucl Med"},{"issue":"1","key":"2022_CR16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2967\/jnumed.117.193888","volume":"59","author":"JE Mortimer","year":"2018","unstructured":"Mortimer JE, Bading JR, Park JM, Frankel PH, Carroll MI, Tran TT, Poku EK, Rockne RC, Raubitschek AA, Shively JE, Colcher DM (2018) Tumor uptake of 64Cu-DOTA-trastuzumab in patients with metastatic breast cancer. J Nucl Med 59(1):38\u201343. https:\/\/doi.org\/10.2967\/jnumed.117.193888","journal-title":"J Nucl Med"},{"key":"2022_CR17","doi-asserted-by":"publisher","first-page":"108115","DOI":"10.1016\/j.bioorg.2024.108115","volume":"155","author":"E Saccullo","year":"2025","unstructured":"Saccullo E, Patamia V, Tomarchio EG, Zagni C, Floresta G, Rescifina A (2025) Unveiling the chemistry of antibody conjugation for enhanced PET imaging: Current trends and future directions. Bioorg Chem. 155:108115. https:\/\/doi.org\/10.1016\/j.bioorg.2024.108115","journal-title":"Bioorg Chem."},{"issue":"47","key":"2022_CR18","doi-asserted-by":"publisher","first-page":"E6525","DOI":"10.1073\/pnas.1502648112","volume":"112","author":"Y Yang","year":"2015","unstructured":"Yang Y, Hernandez R, Rao J, Yin L, Qu Y, Wu J, England CG, Graves SA, Lewis CM, Wang P, Meyerand ME, Nickles RJ, Bian XW, Cai W (2015) Targeting CD146 with a 64Cu-labeled antibody enables in vivo immunoPET imaging of high-grade gliomas. Proc Natl Acad Sci USA 112(47):E6525-34. https:\/\/doi.org\/10.1073\/pnas.1502648112","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"2022_CR19","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1073\/pnas.1418391112","volume":"112","author":"CM Griessinger","year":"2015","unstructured":"Griessinger CM, Maurer A, Kesenheimer C, Kehlbach R, Reischl G, Ehrlichmann W, Bukala D, Harant M, Cay F, Bruck J, Nordin R, Kohlhofer U, Rammensee HG, Quintanilla-Martinez L, Schaller M, Rocken M, Pichler BJ, Kneilling M (2015) 64Cu antibody-targeting of the T-cell receptor and subsequent internalization enables in vivo tracking of lymphocytes by PET. Proc Natl Acad Sci USA 112(4):1161\u20136. https:\/\/doi.org\/10.1073\/pnas.1418391112","journal-title":"Proc Natl Acad Sci USA"},{"issue":"39","key":"2022_CR20","doi-asserted-by":"publisher","first-page":"35884","DOI":"10.1021\/acsomega.3c03614","volume":"8","author":"S SurendraPanikar","year":"2023","unstructured":"SurendraPanikar S, Shmuel S, Lewis JS, Pereira PMR (2023) PET and optical imaging of caveolin-1 in gastric tumors. ACS Omega 8(39):35884\u201335892. https:\/\/doi.org\/10.1021\/acsomega.3c03614","journal-title":"ACS Omega"},{"key":"2022_CR21","doi-asserted-by":"publisher","first-page":"1405485","DOI":"10.3389\/fimmu.2024.1405485","volume":"15","author":"D Ibrahim","year":"2024","unstructured":"Ibrahim D, Sim\u00f3 C, Brown EL, Shmuel S, Panikar SS, Benton A, DeWeerd R, Dehdashti F, Park H, Pereira PMR (2024) PD-L1 has a heterogeneous and dynamic expression in gastric cancer with implications for immunoPET. Front Immunol 15:1405485. https:\/\/doi.org\/10.3389\/fimmu.2024.1405485","journal-title":"Front Immunol"},{"issue":"10","key":"2022_CR22","doi-asserted-by":"publisher","first-page":"e007596","DOI":"10.1136\/jitc-2023-007596","volume":"11","author":"GGW Sandker","year":"2023","unstructured":"Sandker GGW, Middelburg J, Wilbrink E, Molkenboer-Kuenen J, Aarntzen E, van Hall T, Heskamp S (2023) Longitudinal evaluation of the biodistribution and cellular internalization of the bispecific CD3xTRP1 antibody in syngeneic mouse tumor models. J ImmunoTherapy Cancer 11(10):e007596. https:\/\/doi.org\/10.1136\/jitc-2023-007596","journal-title":"J ImmunoTherapy Cancer"},{"issue":"1","key":"2022_CR23","doi-asserted-by":"publisher","first-page":"e000548","DOI":"10.1136\/jitc-2020-000548","volume":"8","author":"SJ Waaijer","year":"2020","unstructured":"Waaijer SJ, Giesen D, Ishiguro T, Sano Y, Sugaya N, Schr\u00f6der CP, de Vries EG, Lub-de Hooge MN (2020) Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate. J ImmunoTher Cancer 8(1):e000548. https:\/\/doi.org\/10.1136\/jitc-2020-000548","journal-title":"J ImmunoTher Cancer"},{"key":"2022_CR24","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","volume":"5","author":"G Vidarsson","year":"2014","unstructured":"Vidarsson G, Dekkers G, Rispens T (2014) IgG subclasses and allotypes: from structure to effector functions. Front Immunol 5:520. https:\/\/doi.org\/10.3389\/fimmu.2014.00520","journal-title":"Front Immunol"},{"issue":"7","key":"2022_CR25","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1158\/0008-5472.CAN-17-1958","volume":"78","author":"SK Sharma","year":"2018","unstructured":"Sharma SK, Chow A, Monette S, Vivier D, Pourat J, Edwards KJ, Dilling TR, Abdel-Atti D, Zeglis BM, Poirier JT, Lewis JS (2018) Fc-mediated anomalous biodistribution of therapeutic antibodies in immunodeficient mouse models. Can Res 78(7):1820\u20131832. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-1958","journal-title":"Can Res"},{"issue":"10","key":"2022_CR26","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s00262-002-0319-x","volume":"51","author":"RB Michel","year":"2002","unstructured":"Michel RB, Ochakovskaya R, Mattes MJ (2002) Rapid blood clearance of injected mouse IgG2a in SCID mice. Cancer Immunol Immunother 51(10):547\u201356. https:\/\/doi.org\/10.1007\/s00262-002-0319-x","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"2022_CR27","first-page":"3102","volume":"51","author":"RM Sharkey","year":"1991","unstructured":"Sharkey RM, Natale A, Goldenberg DM, Mattes MJ (1991) Rapid blood clearance of immunoglobulin G2a and immunoglobulin G2b in nude mice. Cancer Res 51(12):3102\u20133107","journal-title":"Cancer Res"},{"issue":"1","key":"2022_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s002620050456","volume":"46","author":"N Reddy","year":"1998","unstructured":"Reddy N, Ong GL, Behr TM, Sharkey RM, Goldenberg DM, Mattes MJ (1998) Rapid blood clearance of mouse IgG2a and human IgG1 in many nude and nu\/+ mouse strains is due to low IgG2a serum concentrations. Cancer Immunol Immunother 46(1):25\u201333. https:\/\/doi.org\/10.1007\/s002620050456","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"2022_CR29","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s11307-024-01898-x","volume":"26","author":"S Delaney","year":"2024","unstructured":"Delaney S, Grimaldi C, Houghton JL, Zeglis BM (2024) MIB Guides: Measuring the immunoreactivity of radioimmunoconjugates. Mol Imag Biol 26(2):213\u2013221. https:\/\/doi.org\/10.1007\/s11307-024-01898-x","journal-title":"Mol Imag Biol"},{"key":"2022_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-024-01917-x","author":"S Shmuel","year":"2024","unstructured":"Shmuel S, Monette S, Ibrahim D, Pereira PMR (2024) PDX models in theranostic applications: generation and screening for B cell lymphoma of human origin. Mol Imag Biol. https:\/\/doi.org\/10.1007\/s11307-024-01917-x","journal-title":"Mol Imag Biol"},{"issue":"1","key":"2022_CR31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11307-023-01868-9","volume":"26","author":"LM Carter","year":"2024","unstructured":"Carter LM, Zanzonico PB (2024) MIB Guides: preclinical radiopharmaceutical dosimetry. Mol Imag Biol 26(1):17\u201328. https:\/\/doi.org\/10.1007\/s11307-023-01868-9","journal-title":"Mol Imag Biol"},{"issue":"23","key":"2022_CR32","doi-asserted-by":"publisher","first-page":"6215","DOI":"10.1158\/1078-0432.CCR-20-1960","volume":"26","author":"PMR Pereira","year":"2020","unstructured":"Pereira PMR, Mandleywala K, Ragupathi A, Lewis JS (2020) Acute statin treatment improves antibody accumulation in EGFR- and PSMA-expressing tumors. Clin Cancer Res 26(23):6215\u201329. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-1960","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2022_CR33","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1039\/d0cs00310g","volume":"50","author":"SJ Walsh","year":"2021","unstructured":"Walsh SJ, Bargh JD, Dannheim FM, Hanby AR, Seki H, Counsell AJ, Ou X, Fowler E, Ashman N, Takada Y, Isidro-Llobet A, Parker JS, Carroll JS, Spring DR (2021) Site-selective modification strategies in antibody-drug conjugates. Chem Soc Rev 50(2):1305\u201353. https:\/\/doi.org\/10.1039\/d0cs00310g","journal-title":"Chem Soc Rev"},{"issue":"4","key":"2022_CR34","doi-asserted-by":"publisher","first-page":"480","DOI":"10.3390\/ph17040480","volume":"17","author":"F Basuli","year":"2024","unstructured":"Basuli F, Vasalatiy O, Shi J, Lane KC, Escorcia FE, Swenson RE (2024) Preparation of a zirconium-89 labeled clickable DOTA complex and its antibody conjugate. Pharmaceuticals. 17(4):480. https:\/\/doi.org\/10.3390\/ph17040480","journal-title":"Pharmaceuticals."},{"issue":"7","key":"2022_CR35","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1021\/acs.bioconjchem.0c00087","volume":"32","author":"SK Sharma","year":"2021","unstructured":"Sharma SK, Glaser JM, Edwards KJ, KhozeimehSarbisheh E, Salih AK, Lewis JS, Price EW (2021) A systematic evaluation of antibody modification and 89Zr-radiolabeling for optimized immuno-PET. Bioconjugate Chem 32(7):1177\u201391. https:\/\/doi.org\/10.1021\/acs.bioconjchem.0c00087","journal-title":"Bioconjugate Chem"},{"issue":"4","key":"2022_CR36","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nprot.2010.13","volume":"5","author":"MJ Vosjan","year":"2010","unstructured":"Vosjan MJ, Perk LR, Visser GW, Budde M, Jurek P, Kiefer GE, van Dongen GA (2010) Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat Protoc 5(4):739\u201343. https:\/\/doi.org\/10.1038\/nprot.2010.13","journal-title":"Nat Protoc"},{"issue":"8","key":"2022_CR37","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.2967\/jnumed.121.262940","volume":"63","author":"JE Mortimer","year":"2022","unstructured":"Mortimer JE, Bading JR, Frankel PH, Carroll MI, Yuan Y, Park JM, Tumyan L, Gidwaney N, Poku EK, Shively JE, Colcher DM (2022) Use of 64Cu-DOTA-Trastuzumab PET to predict response and outcome of patients receiving trastuzumab emtansine for metastatic breast cancer: A pilot study. J Nucl Med 63(8):1145\u20138. https:\/\/doi.org\/10.2967\/jnumed.121.262940","journal-title":"J Nucl Med"},{"issue":"3","key":"2022_CR38","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1021\/acsabm.0c01555","volume":"4","author":"W Lee","year":"2021","unstructured":"Lee W, Sarkar S, Pal R, Kim JY, Park H, Huynh PT, Bhise A, Bobba KN, Kim KI, Ha YS, Soni N, Kim W, Lee K, Jung JM, Rajkumar S, Lee KC, Yoo J (2021) Successful application of CuAAC Click reaction in constructing 64Cu-labeled antibody conjugates for immuno-PET imaging. ACS Appl Bio Mater. 4(3):2544\u201357. https:\/\/doi.org\/10.1021\/acsabm.0c01555","journal-title":"ACS Appl Bio Mater."},{"issue":"3","key":"2022_CR39","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1021\/acs.molpharmaceut.8b01052","volume":"16","author":"Q Ren","year":"2019","unstructured":"Ren Q, Mohri K, Warashina S, Wada Y, Watanabe Y, Mukai H (2019) Improved immuno-PET imaging of HER2-positive tumors in mice: Urokinase injection-triggered clearance enhancement of 64Cu-trastuzumab. Mol Pharm. 16(3):1065\u201373. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b01052","journal-title":"Mol Pharm."},{"issue":"9","key":"2022_CR40","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.1039\/d4sc06969b","volume":"16","author":"SE Rudd","year":"2025","unstructured":"Rudd SE, Van Zuylekom J, Cullinane C, Blyth BJ, Donnelly PS (2025) Potential theranostics of breast cancer with copper-64\/67 sarcophagine-trastuzumab. Chem Sci 16(9):3998\u20134005. https:\/\/doi.org\/10.1039\/d4sc06969b","journal-title":"Chem Sci"},{"issue":"5","key":"2022_CR41","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1021\/bc300037w","volume":"23","author":"MS Cooper","year":"2012","unstructured":"Cooper MS, Ma MT, Sunassee K, Shaw KP, Williams JD, Paul RL, Donnelly PS, Blower PJ (2012) Comparison of 64Cu-complexing bifunctional chelators for radioimmunoconjugation: labeling efficiency, specific activity, and in vitro\/in vivo stability. Bioconjug Chem 23(5):1029\u201339. https:\/\/doi.org\/10.1021\/bc300037w","journal-title":"Bioconjug Chem"},{"issue":"6","key":"2022_CR42","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1002\/jps.22034","volume":"99","author":"MD Bond","year":"2010","unstructured":"Bond MD, Panek ME, Zhang Z, Wang D, Mehndiratta P, Zhao H, Gunton K, Ni A, Nedved ML, Burman S, Volkin DB (2010) Evaluation of a dual-wavelength size exclusion HPLC method with improved sensitivity to detect protein aggregates and its use to better characterize degradation pathways of an IgG1 monoclonal antibody. J Pharm Sci 99(6):2582\u20132597. https:\/\/doi.org\/10.1002\/jps.22034","journal-title":"J Pharm Sci"},{"issue":"10","key":"2022_CR43","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1248\/cpb.c21-00258","volume":"69","author":"Y Matsuda","year":"2021","unstructured":"Matsuda Y, Mendelsohn BA (2021) Recent advances in drug-antibody ratio determination of antibody-drug conjugates. Chem Pharm Bull (Tokyo) 69(10):976\u2013983. https:\/\/doi.org\/10.1248\/cpb.c21-00258","journal-title":"Chem Pharm Bull (Tokyo)"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-025-02022-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11307-025-02022-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-025-02022-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T07:02:34Z","timestamp":1756882954000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11307-025-02022-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,26]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2022"],"URL":"https:\/\/doi.org\/10.1007\/s11307-025-02022-3","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,26]]},"assertion":[{"value":"21 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}